ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/JAK2
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/JAK2
7
trial(s) found.
NCT06479135
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib Vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (
POIESIS
)
JAK1/JAK2 inhibitor
MDM2 inhibitor
placebo
Myelofibrosis
NSW
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05936359
Haem
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (
2022-502514-86-00--INCA-33989-101
)
JAK1/JAK2 inhibitor
anti-CALR monoclonal antibody
Myeloproliferative Neoplasm
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05037760
Haem
Phase 2
Recruiting
A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis (
KER050-MF-301
)
JAK1/JAK2 inhibitor
modified ActRIIA ligand trap protein
Myelofibrosis
NSW
2139 - Concord - Concord Repatriation General Hospital
2485 - Tweed Heads - The Tweed Hospital
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
3066 - Epping - Northern Hospital
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT04176198
Haem
Phase 1
Recruiting
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis (
BBI-TP-3654-102
)
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
Momelotinib
Ruxolitinib
cancer therapy
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
+ JAK1/JAK2 inhibitor
Myelofibrosis
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT03165734
Haem
Phase 3
Recruiting
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/µL)(
PACIFICA
)
JAK2 inhibitor
Myelofibrosis
Polycythemia vera
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
NCT02386800
Haem
Phase 4
Recruiting
Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies (
2014-003527-22--CINC424A2X01B
)
JAK1/JAK2 inhibitor
pan-HDAC inhibitor
Acute myeloid leukaemia
Myelofibrosis
Polycythemia vera
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6000 - Perth - Royal Perth Hospital
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ JAK1/JAK2 inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (6)
Status unknown (1)
Recruitment Country and State
VIC (6)
SA (5)
NSW (4)
QLD (3)
WA (3)
Phase
Phase 1 (2)
Phase 2 (1)
Phase 3 (2)
Phase 4 (1)
Trial Type
Haem (6)
Advanced (1)
Cancer Therapy Class
JAK1
100%
JAK2
100%
MDM2
14%
CALR
14%
HDAC
14%
pan-HDAC
14%
ALK
14%
ATR
14%
BCR-ABL1
14%
CDK4
14%
CDK6
14%
CRAF
14%
EGFR
14%
FLT3
14%
KIT
14%
MET
14%
PDGFR
14%
PDGFRA
14%
PI3K
14%
RAF
14%
ROS1
14%
SMO
14%
SRC
14%
VEGFR
14%
YES1
14%
mTOR
14%
mTORC1
14%
mTORC2
14%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
3168 - Clayton - Monash Medical Centre (3)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (3)
3004 - Melbourne, Southbank - Alfred Health (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
6000 - Perth - Royal Perth Hospital (2)
2217 - Kogarah - St George Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2485 - Tweed Heads - The Tweed Hospital (1)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
3066 - Epping - Northern Hospital (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
NA
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
Cancer Type
Cancer
Haematological malignancy
Myeloproliferative neoplasm
Myelofibrosis
Polycythemia vera
Acute myeloid leukaemia
Leukaemia
Myeloid leukaemia
Head and neck cancer
Solid tumour
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy